Physician profile
Stevenson Brisson Chery
NPI 1144723958
$980.70
in general payments reported to CMS, 2019-2025
12 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $29.81 · 2022: $36.46 · 2023: $366 · 2024: $402 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $914.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $914.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $362.15 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Viiv Healthcare Company | $214.67 | 2023-2025 | Dovato, Apretude |
| Abbott Laboratories | $100.19 | 2021-2024 | Freestyle Libre 3, Proclaim, Freestyle Libre |
| Gilead Sciences, INC. | $89.62 | 2023-2024 | |
| Lilly USA, LLC | $81.29 | 2023-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.00 | 2024 | Synjardy, Jardiance |
| Hologic Sales and Service, LLC | $21.68 | 2023 | Aptima |
| Pfizer INC. | $20.42 | 2024 | |
| Dexcom, INC. | $19.63 | 2025 | Dexcom G6 Transmitter |
| Organon LLC | $18.67 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $17.21 | 2022 | |
| Glaxosmithkline, LLC. | $11.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stevenson Chery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.